moderna goldman sachs

Moderna slips

Moderna Stock Falls After Goldman Downgrade. Vaccine Sales Are a Worry.

Goldman Sachs downgraded the vaccine maker to Neutral from Buy and slashed its stock-price target to $51 from $99 Wednesday.

Seeking Alpha on MSN · 1d

Moderna slips as Goldman Sachs downgrades on revenue outlook

Moderna (MRNA) stock falls as Goldman Sachs downgrades the COVID-19 vaccine maker to Neutral from Buy, citing a lack of clarity over its revenue outlook. Read more here.

Business Insider · 1d

Moderna downgraded to Neutral from Buy at Goldman Sachs

Goldman Sachs downgraded Moderna (MRNA) to Neutral from Buy with a price target of $51, down from $99. The recent product revenue guidance

18hon MSN

Why Moderna (MRNA) Crashed on Wednesday?

We recently published a list of These 10 Stocks Were Wednesday’s Worst Performers. In this article, we are going to take a ...

Moderna Stock Is Sliding Wednesday: Here's Why

Moderna Inc (NASDAQ:MRNA) shares are trading lower Wednesday after Goldman Sachs downgraded the stock. Here's what you need ...

Moderna Hold Recommendation Amid Reduced Revenue Projections and Price Target

In a report released today, Tyler Van Buren from TD Cowen maintained a Hold rating on Moderna (MRNA – Research Report), with a price target of ...

The Motley Fool15d

Goldman Sachs Surges Past Q4 Forecasts

Goldman Sachs' Q4 2024 earnings per share (EPS) soared to $11.95, significantly surpassing the expected $8.21. Revenue in Q4 hit $13.87 billion, exceeding estimates of $12.36 billion. Fourth ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results